X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8502) 8502
Book Chapter (85) 85
Newspaper Article (30) 30
Newsletter (26) 26
Transcript (12) 12
Magazine Article (11) 11
Publication (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6489) 6489
male (2826) 2826
female (2523) 2523
anticoagulants (2453) 2453
hematology (2090) 2090
animals (1986) 1986
risk factors (1980) 1980
anticoagulants - therapeutic use (1656) 1656
peripheral vascular disease (1634) 1634
anticoagulants - administration & dosage (1562) 1562
aged (1525) 1525
middle aged (1505) 1505
rivaroxaban (1489) 1489
administration, oral (1484) 1484
factor xa inhibitors (1390) 1390
warfarin (1338) 1338
anticoagulants - adverse effects (1297) 1297
venous thromboembolism (1269) 1269
thrombosis (1260) 1260
treatment outcome (1185) 1185
prevention (1168) 1168
thromboembolism (1095) 1095
pharmacology & pharmacy (1082) 1082
adult (1080) 1080
cardiac & cardiovascular systems (1034) 1034
thrombin (1003) 1003
atrial fibrillation (986) 986
dabigatran (961) 961
hemorrhage - chemically induced (961) 961
stroke (914) 914
blood coagulation - drug effects (848) 848
care and treatment (844) 844
coagulation (805) 805
heparin (798) 798
molecular-weight heparin (795) 795
medicine & public health (780) 780
analysis (761) 761
time factors (750) 750
drug therapy (727) 727
atrial fibrillation - drug therapy (722) 722
apixaban (709) 709
anticoagulants - pharmacology (701) 701
health aspects (680) 680
research (678) 678
factor xa inhibitor (667) 667
dose-response relationship, drug (663) 663
stroke - prevention & control (662) 662
anticoagulation (656) 656
aged, 80 and over (640) 640
factor xa inhibitors - administration & dosage (632) 632
surgery (613) 613
deep-vein thrombosis (612) 612
abridged index medicus (597) 597
enoxaparin (594) 594
dosage and administration (588) 588
tissue factor (587) 587
mice (584) 584
pharmacokinetics (582) 582
atrial fibrillation - complications (559) 559
bleeding (558) 558
safety (549) 549
management (535) 535
atrial-fibrillation (530) 530
patients (526) 526
risk (518) 518
cardiology (511) 511
therapy (511) 511
medicine, general & internal (503) 503
mortality (503) 503
factor xa inhibitors - therapeutic use (498) 498
hemorrhage (493) 493
rats (490) 490
risk assessment (479) 479
factor xa (472) 472
venous thromboembolism - prevention & control (466) 466
factor xa inhibitors - adverse effects (465) 465
double-blind (461) 461
dabigatran etexilate (460) 460
inflammation (451) 451
risk-factors (442) 442
internal medicine (420) 420
unfractionated heparin (419) 419
clinical trials (418) 418
complications and side effects (411) 411
stroke - etiology (405) 405
review (404) 404
fibrinolytic agents - therapeutic use (403) 403
proteins (401) 401
thromboembolism - prevention & control (400) 400
partial thromboplastin time (396) 396
factor-xa inhibitor (389) 389
thromboprophylaxis (386) 386
retrospective studies (382) 382
in-vitro (380) 380
cancer (371) 371
prospective studies (370) 370
blood (368) 368
oral anticoagulants (366) 366
anticoagulants - pharmacokinetics (365) 365
aspirin (361) 361
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8476) 8476
German (64) 64
French (42) 42
Japanese (34) 34
Spanish (27) 27
Russian (22) 22
Italian (10) 10
Polish (7) 7
Hungarian (6) 6
Czech (4) 4
Portuguese (4) 4
Swedish (4) 4
Norwegian (3) 3
Chinese (2) 2
Danish (2) 2
Turkish (2) 2
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 635 - 641.e2
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2012, Volume 108, Issue 5, pp. 876 - 886
.... Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor... 
Recommendations | rivaroxaban | practical management | anticoagulant | Consensus Paper | Rivaroxaban | Anticoagulant | Practical management | ENOXAPARIN | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | recommendations | VENOUS THROMBOEMBOLISM | ANTITHROMBOTIC AGENTS | PHARMACOKINETICS | ASSAYS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Male | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Venous Thromboembolism - prevention & control | Benzimidazoles - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Venous Thrombosis - drug therapy | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Clinical Trials as Topic | Anticoagulants - adverse effects | Pregnancy | Practice Guidelines as Topic | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 14, pp. 1326 - 1335
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2018, Volume 391, Issue 10117, pp. 219 - 229
...) inhibitors, and antiplatelet agents (aspirin or a P2Y12 inhibitor) are used to reduce vascular complications.4-6 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants |